Начало › Колоректален рак › Тексас › San Antonio
Клинични проучвания за Колоректален рак в San Antonio, TX
46 проучвания за Колоректален рак търсят участници в обекти в и около San Antonio (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Набиране на участнициФаза 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- Audie L Murphy VA Hospital, San Antonio
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Набиране на участнициФаза 1
- University of Texas San Antonio (UTSA), San Antonio
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Набиране на участнициФаза 3
- Texas Oncology - San Antonio, San Antonio
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Набиране на участнициФаза 3
- Texas Oncology - San Antonio, San Antonio
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1
- START San Antonio, San Antonio
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Набиране на участнициФаза 2/3
- Texas Oncology - San Antonio, San Antonio
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Набиране на участнициФаза 1/2
- NEXT Oncology San Antonio, San Antonio
- START Texas, San Antonio
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Набиране на участнициФаза 1
- NEXT, San Antonio
- START - San Antonio, San Antonio
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Набиране на участнициФаза 1/2
- START San Antonio, San Antonio
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1
- NEXT Oncology, San Antonio
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Набиране на участнициФаза 3
- Texas Oncology- San Antonio, San Antonio
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Набиране на участнициФаза 2
- Mays Cancer Center at University of Texas Health at San Antonio, San Antonio
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Набиране на участнициФаза 1
- NEXT San Antonio, San Antonio
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Набиране на участнициФаза 1
- NEXT Oncology, San Antonio
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Набиране на участнициФаза 1
- South Texas Accelerated Research Therapeutics (START), San Antonio
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- UT Health Mays Cancer Center, San Antonio
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- Clinical Trial Site, San Antonio
IDOV-Immune for Advanced Solid Tumors
Набиране на участнициФаза 1
- South Texas Accelerated Research Therapeutics, San Antonio
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Набиране на участнициФаза 1/2
- GSK Investigational Site, San Antonio
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Набиране на участнициФаза 1/2
- NEXT Oncology, San Antonio
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- Texas Oncology - San Antonio, San Antonio
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- Next Oncology, San Antonio
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Набиране на участнициФаза 1
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- START San Antonio, San Antonio
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1
- START San Antonio, LLC., San Antonio
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Набиране на участнициФаза 1
- New Experimental Therapeutics of San Antonio LLC, San Antonio
- START - South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Набиране на участнициФаза 1/2
- Next Oncology-Oncology, San Antonio
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Набиране на участнициФаза 1
- NEXT Oncology, San Antonio
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Набиране на участнициФаза 1
- NEXT Texas LLC - San Antonio, San Antonio
- START San Antonio, LLC, San Antonio
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Набиране на участнициФаза 1
- NEXT Texas LLC - San Antonio, San Antonio
- Start San Antonio, LLC, San Antonio
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Набиране на участнициФаза 1
- Context Investigational Site, San Antonio
- Context Investigational Site, San Antonio
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Набиране на участнициФаза 1
- Research Site #2, San Antonio
- Research Site, San Antonio
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Набиране на участнициФаза 1
- START, San Antonio
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Набиране на участнициФаза 1
- NEXT Oncology, San Antonio
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Набиране на участнициФаза 1/2
- NEXT Oncology, San Antonio
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Набиране на участнициФаза 1/2
- Next Oncology, San Antonio
A Study of MGC028 in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Набиране на участнициФаза 1/2
- NEXT Oncology, San Antonio
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Набиране на участнициФаза 1
- NEXT Oncology, San Antonio
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Набиране на участнициФаза 1
- NEXT Oncology, San Antonio
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Набиране на участнициФаза 1/2
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
- UT Health San Antonio, San Antonio
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- START San Antonio, San Antonio
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Набиране на участнициФаза 1/2
- START San Antonio, San Antonio
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Набиране на участнициФаза 1/2
- Next Oncology, San Antonio, San Antonio
Проучвания за Колоректален рак в други градове
- Houston, TX102 проучвания
- New York City, NY78 проучвания
- Nashville, TN69 проучвания
- Boston, MA63 проучвания
- Los Angeles, CA59 проучвания
- Arlington, VA52 проучвания
- St. Louis, MO50 проучвания
- Philadelphia, PA44 проучвания
- Grand Rapids, MI40 проучвания
- Baldwin Park, CA37 проучвания
- Chicago, IL34 проучвания
- Tampa, FL34 проучвания
Други проучвания в San Antonio
- Рак на белия дроб с недребноклетъчен тип59 проучвания
- Рак на гърдата47 проучвания
- Метастатичен рак44 проучвания
- Рак (всички видове)41 проучвания
- Затлъстяване40 проучвания
- Диабет тип 237 проучвания
- Наднормено тегло34 проучвания
- Рак на яйчниците31 проучвания
- Рак на панкреаса31 проучвания
- Рак на простатата28 проучвания
- Ендометриален рак27 проучвания
- Рак на белия дроб26 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.